Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies
Open accessAbstract
Recent advances in the management of cystic fibrosis (CF) target underlying defects in the CF transmembrane conductance regulator (CFTR) protein, but efficacy analyses remain limited to specific genotype–based subgroups. Patient-derived model systems may therefore aid in expanding access to these drugs. Brushed human nasal epithelial cells (HNEs) are an attractive tissue source, but it remains unclear how faithfully they recapitulate human bronchial epithelial cell (HBE) CFTR activity. We examined this gap using paired, brushed HNE/HBE samples from pediatric CF subjects with a wide variety of CFTR mutations cultured at the air-liquid interface. Growth and structural characteristics for the two cell types were similar, including differentiation into mature respiratory epithelia. In electrophysiologic analysis, no correlation was identified between nasal and bronchial cultures in baseline resistance or epithelial sodium channel (ENaC) activity. Conversely, robust correlation was demonstrated between nasal and bronchial cultures in both stimulated and inhibited CFTR activity. There was close correlation in modulator-induced change in CFTR activity, and CFTR activity in both cell types correlated with in vivo sweat chloride measurements. These data confirm that brushed HNE cell cultures recapitulate the functional CFTR characteristics of HBEs with fidelity and are therefore an appropriate noninvasive HBE surrogate for individualized CFTR analysis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Patient-derived HNE are precision medicine tools that can predict clinical responsiveness of individuals and likely inform on the theratype of individual mutations or mutation combinations.
“Patient-derived HNE are precision medicine tools that can predict the clinical responsiveness of individuals and likely inform on the theratype of individual mutations or mutation combinations (38–40).”
From Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination (2020) · cites this paper as [40]
Cites
Understanding bland altman analysis
Giavarina, D. (2015) · Biochemia Medica · doi:10.11613/bm.2015.015 · Cited by 4,022 · see citing works
Gibson, L. E., & Cooke, R. E. (1959) · Pediatrics · doi:10.1542/peds.23.3.545 · Cited by 1,434 · see citing works
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Veit, G., Roldan, A., Hancock, M. A., Da Fonte, D. F., Xu, H., Hussein, M., Frenkiel, S., Matouk, E., Velkov, T., & Lukacs, G. L. (2020) · JCI Insight · doi:10.1172/jci.insight.139983 · Cited by 250 · see citing works
Awatade, N. T., Wong, S. L., Hewson, C. K., Fawcett, L. K., Kicic, A., Jaffe, A., & Waters, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01429 · Cited by 92 · see citing works
- Authors
- Brewington, J. J., Filbrandt, E. T., LaRosa, F. J., Moncivaiz, J. D., Ostmann, A. J., Strecker, L. M., & Clancy, J. P.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Brewington, John J.
- Venue
- JCI Insight
- Published
- 2018-07-12
- Volume
- 3
- Issue
- 13
- ISSN
- 2379-3708 (ISSN-L)
- PMC
- PMC6124537
- OpenAlex
- W2866605691
- Cited by
- 106
- References
- 3
- Citations by year
- 2026: 14 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 20 · 2021: 22 · 2020: 13 · 2019: 9 · 2018: 2
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- JCI Insight (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cystic Fibrosis Foundation (CLANCY15R0)
- Cystic Fibrosis Foundation Therapeutics (CLANCY14XX0)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- cystic fibrosis, CFTR, nasal epithelial cells, bronchial epithelial cells, air-liquid interface culture, CFTR modulators, epithelial sodium channel, sweat chloride, patient-derived models, pediatric cystic fibrosis
- MeSH terms
- Biological Transport, Bronchi, Cells, Cultured, Cystic Fibrosis, Epithelial Cells, Humans, Mutation, Sodium Channels, Cystic Fibrosis Transmembrane Conductance Regulator, Respiratory Mucosa, Tissue Culture Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review